BlueMountain Capital Management LLC Buys Shares of 90,760 MEDNAX Inc (MD)

Share on StockTwits

BlueMountain Capital Management LLC bought a new position in MEDNAX Inc (NYSE:MD) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 90,760 shares of the company’s stock, valued at approximately $3,928,000. BlueMountain Capital Management LLC owned 0.10% of MEDNAX at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Fort Washington Investment Advisors Inc. OH increased its holdings in MEDNAX by 55.7% in the 2nd quarter. Fort Washington Investment Advisors Inc. OH now owns 363,201 shares of the company’s stock valued at $15,719,000 after purchasing an additional 130,001 shares in the last quarter. Bank of Montreal Can increased its holdings in MEDNAX by 6.8% in the 2nd quarter. Bank of Montreal Can now owns 210,277 shares of the company’s stock valued at $9,102,000 after purchasing an additional 13,360 shares in the last quarter. Legal & General Group Plc increased its holdings in MEDNAX by 16.4% in the 1st quarter. Legal & General Group Plc now owns 137,616 shares of the company’s stock valued at $7,655,000 after purchasing an additional 19,421 shares in the last quarter. Pzena Investment Management LLC increased its holdings in MEDNAX by 1.8% in the 2nd quarter. Pzena Investment Management LLC now owns 2,299,800 shares of the company’s stock valued at $99,535,000 after purchasing an additional 41,088 shares in the last quarter. Finally, State of Alaska Department of Revenue increased its holdings in MEDNAX by 40.1% in the 2nd quarter. State of Alaska Department of Revenue now owns 10,030 shares of the company’s stock valued at $434,000 after purchasing an additional 2,870 shares in the last quarter. 95.50% of the stock is currently owned by institutional investors and hedge funds.

MD has been the subject of several recent research reports. Zacks Investment Research downgraded MEDNAX from a “hold” rating to a “sell” rating in a report on Tuesday, July 3rd. Credit Suisse Group upgraded MEDNAX from a “neutral” rating to an “outperform” rating and increased their price target for the company from $47.00 to $55.00 in a report on Friday, August 3rd. Leerink Swann initiated coverage on MEDNAX in a report on Thursday, July 12th. They issued a “market perform” rating and a $50.00 price target for the company. Stifel Nicolaus set a $47.00 price target on MEDNAX and gave the company a “hold” rating in a report on Thursday, August 2nd. Finally, ValuEngine upgraded MEDNAX from a “strong sell” rating to a “sell” rating in a report on Friday, August 3rd. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $54.71.

In related news, CFO Vivian Lopez-Blanco sold 13,942 shares of MEDNAX stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $46.46, for a total value of $647,745.32. Following the completion of the transaction, the chief financial officer now directly owns 100,590 shares in the company, valued at $4,673,411.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John C. Pepia sold 3,500 shares of MEDNAX stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $48.18, for a total value of $168,630.00. Following the completion of the transaction, the insider now owns 30,148 shares of the company’s stock, valued at $1,452,530.64. The disclosure for this sale can be found here. Insiders have sold 41,958 shares of company stock valued at $1,964,860 over the last 90 days. Insiders own 2.40% of the company’s stock.

Shares of MEDNAX stock opened at $47.37 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.52 and a quick ratio of 1.52. The stock has a market cap of $4.47 billion, a PE ratio of 15.04, a price-to-earnings-growth ratio of 1.29 and a beta of 0.24. MEDNAX Inc has a 1-year low of $40.56 and a 1-year high of $63.04.

MEDNAX (NYSE:MD) last announced its earnings results on Thursday, August 2nd. The company reported $1.07 earnings per share for the quarter, meeting the consensus estimate of $1.07. The company had revenue of $915.90 million during the quarter, compared to the consensus estimate of $911.77 million. MEDNAX had a return on equity of 10.42% and a net margin of 9.59%. The company’s revenue was up 8.6% on a year-over-year basis. During the same period last year, the firm earned $0.85 earnings per share. analysts predict that MEDNAX Inc will post 3.7 EPS for the current fiscal year.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

See Also: Growth Stocks

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply